Ozempic for Heart Failure: Off-Label Risks, Tradeoffs, and What the Evidence Shows

FDA-Approved Indications vs. Off-Label Reality

Ozempic carries FDA approval exclusively for glycemic control in type 2 diabetes at doses of 0.5 mg, 1.0 mg, and 2.0 mg once weekly 1. The label does not mention heart failure treatment. Semaglutide 2.4 mg (marketed as Wegovy) holds a separate cardiovascular indication for reducing major adverse cardiovascular events (MACE) in adults with established CVD and BMI ≥27, based on the SELECT trial 2. That cardiovascular indication is specific to MACE reduction, not heart failure management.

When clinicians prescribe Ozempic for heart failure, they are operating outside both approved indications. The dose range available through Ozempic (max 2.0 mg) is also lower than what was studied in the cardiac-focused trials. This distinction matters. SELECT used 2.4 mg. STEP-HFpEF used 2.4 mg. No randomized trial has tested the 0.5-2.0 mg dose range specifically for heart failure endpoints 3.

STEP-HFpEF: The Central Trial

The STEP-HFpEF trial (N=529) enrolled patients with HFpEF (ejection fraction ≥45%), BMI ≥30, and NYHA class II-IV symptoms 4. Participants received semaglutide 2.4 mg weekly or placebo for 52 weeks. The dual primary endpoints were change in KCCQ clinical summary score and change in body weight.

Results were notable. KCCQ score improved by 16.6 points with semaglutide versus 8.7 with placebo (estimated difference 7.8 points; 95% CI 4.8 to 10.9; P<0.001). Body weight decreased by 13.3% vs. 2.6%. The 6-minute walk distance improved by 21.5 meters more with semaglutide than placebo 4. C-reactive protein fell by 38.8% in the semaglutide group, suggesting systemic anti-inflammatory effects 5.

Dr. Mikhail Kosiborod, lead investigator, stated: "The improvements in symptoms, physical limitations, and exercise function were large and clinically meaningful, well beyond the thresholds considered important to patients" 4.

A key limitation: STEP-HFpEF excluded patients with EF <45%, those with HFrEF, and those with BMI <30. The trial measured symptoms, not hard outcomes like mortality or hospitalization over multiple years.

STEP-HFpEF DM: The Diabetes Subpopulation

STEP-HFpEF DM (N=616) enrolled HFpEF patients with concomitant type 2 diabetes and BMI ≥30 6. At 52 weeks, KCCQ improved by 13.7 points with semaglutide 2.4 mg versus 6.4 with placebo (difference 7.3 points; P<0.001). Weight loss was 9.8% vs. 3.4%. The 6-minute walk distance difference was 14.3 meters favoring semaglutide 6.

These results mirrored STEP-HFpEF but with somewhat smaller effect sizes for weight loss. The diabetes subgroup still demonstrated clinically significant symptom improvement, reinforcing that the benefit likely operates through both weight-dependent and weight-independent mechanisms 7.

SELECT Trial: Cardiovascular Outcomes but Not Heart Failure

SELECT (N=17,604) randomized adults with BMI ≥27 and established atherosclerotic CVD (without diabetes) to semaglutide 2.4 mg or placebo 2. Over a median 39.8 months, MACE occurred in 6.5% of semaglutide patients versus 8.0% with placebo (HR 0.80; 95% CI 0.72 to 0.90; P<0.001). That is a 20% relative risk reduction.

Heart failure hospitalization was a secondary or exploratory endpoint. The prespecified composite of cardiovascular death or heart failure events showed a numerical reduction that did not reach statistical significance for the HF component alone in the primary analysis 8. SELECT does not provide standalone evidence that semaglutide prevents or treats heart failure. It provides evidence of atherosclerotic event reduction 2.

The Dose Problem: 2.0 mg vs. 2.4 mg

This point cannot be overstated. Every positive cardiac trial of semaglutide used 2.4 mg weekly. Ozempic's maximum approved dose is 2.0 mg. The 2.4 mg dose is available only through Wegovy, which carries a different NDC, a different indication, and different insurance pathways 9.

A 17% dose difference (2.0 vs. 2.4 mg) may seem minor. But GLP-1 receptor agonist dose-response curves for weight loss are not linear at the upper end 10. In SUSTAIN 7, semaglutide 1.0 mg produced 1.0% greater HbA1c reduction than 0.5 mg, but weight effects diverged more substantially at higher doses 11. Extrapolating STEP-HFpEF results to Ozempic 2.0 mg requires assumptions about dose-response that remain untested in HFpEF populations.

Risks Specific to Heart Failure Patients

Heart failure patients face distinct vulnerabilities when taking GLP-1 receptor agonists. Gastrointestinal side effects (nausea in 20-44% of patients in SUSTAIN trials, vomiting in 5-15%) can cause dehydration that worsens preload-dependent hemodynamics 12.

Lean mass loss is a specific concern. In STEP-HFpEF, semaglutide reduced total body mass, and dual-energy X-ray absorptiometry substudy data indicated that approximately 40% of weight lost was lean mass 13. For patients with HF-related sarcopenia or cardiac cachexia, losing additional muscle mass could impair functional capacity in ways that offset symptom improvements from fat loss 14.

Heart rate increases of 3-4 beats per minute are consistently observed with semaglutide across trials 2. In compensated HFpEF patients, this small chronotropic effect has unclear consequences. In decompensated or tachycardia-prone patients, it could be clinically relevant.

Dr. Javed Butler, coauthor on STEP-HFpEF, noted: "These agents should not be viewed as heart failure drugs per se. They are obesity drugs that may benefit the HFpEF phenotype driven by excess adiposity" 15.

Who Was Excluded from the Trials

The absence of certain populations from STEP-HFpEF matters for off-label prescribing decisions. Excluded groups include: patients with HFrEF (EF <45%), BMI <30, type 1 diabetes, prior bariatric surgery within 2 years, GLP-1 RA use within 90 days, eGFR <30 mL/min/1.73m², and planned cardiac surgery 4.

Patients with NYHA class IV symptoms made up only 1% of enrolled participants. The trial population was overwhelmingly class II-III, ambulatory, and clinically stable. Applying these results to acutely decompensated patients or those with reduced ejection fraction has no evidentiary basis 16.

Comparison to Guideline-Directed HF Therapies

The 2022 AHA/ACC/HFSA guideline for heart failure management recommends SGLT2 inhibitors (empagliflozin, dapagliflozin) as Class I therapy for HFrEF and Class IIa for HFpEF 17. GLP-1 receptor agonists do not appear in these guidelines as recommended HF therapy.

SGLT2 inhibitors have demonstrated hard-outcome benefits in HFpEF. EMPEROR-Preserved (N=5,988) showed empagliflozin reduced cardiovascular death or HF hospitalization by 21% (HR 0.79; 95% CI 0.69 to 0.90) 18. DELIVER (N=6,263) showed dapagliflozin reduced the same composite by 18% (HR 0.82; 95% CI 0.73 to 0.92) 19. These trials measured what STEP-HFpEF did not: hospitalizations and death.

For patients with HFpEF and obesity, the clinical question is not whether semaglutide helps symptoms (it does, per STEP-HFpEF). The question is whether symptom improvement translates to fewer hospitalizations and longer survival, and whether adding semaglutide to SGLT2 inhibitor therapy provides additive benefit. Neither question has a definitive answer yet 20.

Earlier GLP-1 Trials in HFrEF: A Cautionary Note

Before STEP-HFpEF, two earlier trials tested GLP-1-based therapies in heart failure with reduced EF. The FIGHT trial (N=300) tested liraglutide in patients hospitalized for HFrEF and found no benefit. The primary endpoint (global rank score including death, HF hospitalization, and time-averaged NT-proBNP change) showed no significant difference, and there was a numerical trend toward more adverse events 21.

The LIVE trial (N=241) similarly found liraglutide did not improve LVEF in stable HFrEF patients with or without diabetes. Serious cardiac adverse events were numerically higher in the liraglutide group (12 vs. 3) 22. These were liraglutide trials, not semaglutide. But they establish that GLP-1 receptor agonism is not universally beneficial across HF phenotypes. The mechanism appears specific to the obesity-driven HFpEF phenotype.

Insurance, Access, and Practical Barriers

Prescribing Ozempic off-label for heart failure creates immediate insurance friction. Most payers require documented type 2 diabetes for Ozempic coverage. Prior authorization for cardiac indications will be denied absent a diabetes diagnosis in most formulary structures 23.

Wegovy (semaglutide 2.4 mg) with its cardiovascular indication may be covered for patients with established CVD and BMI ≥27, depending on the payer. But the cardiovascular indication is for MACE reduction, not heart failure treatment. Clinicians face a situation where the dose with supporting evidence (2.4 mg) maps to a product (Wegovy) whose indication still does not encompass heart failure, while the product patients can access for off-label cardiac use (Ozempic) was studied at a different dose for a different purpose.

What Guidelines and Societies Currently Say

The 2022 AHA/ACC/HFSA guideline does not recommend GLP-1 agonists for HF 17. The Endocrine Society's 2024 obesity guideline recommends GLP-1 RAs for weight management in eligible patients but does not position them as cardiac therapy 24. The European Society of Cardiology 2023 focused update on HF mentions GLP-1 RAs only in the context of diabetes management, not as primary HF treatment 25.

No major cardiology or endocrinology society currently endorses semaglutide of any dose as a treatment for heart failure. STEP-HFpEF generated strong signals, and outcome trials are ongoing (STEP-HFpEF-II is evaluating hard endpoints). Until those results are available, off-label use remains a clinical judgment call with moderate-quality evidence supporting symptom benefit and no evidence supporting mortality reduction.

Clinical Decision Framework for Off-Label Consideration

For clinicians considering off-label semaglutide in HF patients, several factors should inform the decision. The patient profile most consistent with available evidence is: HFpEF (EF ≥45%), BMI ≥30, NYHA class II-III, stable on guideline-directed therapy including an SGLT2 inhibitor, no advanced CKD, and no history of pancreatitis or medullary thyroid carcinoma family history 4.

Patients who do NOT fit the evidence profile: HFrEF, BMI <30, NYHA class IV, actively decompensated, or those with significant sarcopenia where lean mass preservation is the priority. For these patients, guideline-directed therapies (ACEi/ARB/ARNI, beta-blockers, MRAs, SGLT2i, and hydralazine/isosorbide dinitrate in appropriate populations) remain the evidence-based approach 17.

Monitoring should include serial body composition assessment (not just scale weight), NT-proBNP trends, functional capacity via 6-minute walk or cardiopulmonary exercise testing, and close attention to volume status during GI side-effect periods. Patients initiated on semaglutide who develop persistent nausea require diuretic dose reassessment to prevent hypovolemia.

The starting dose for any off-label cardiac consideration should follow standard GLP-1 RA titration: semaglutide 0.25 mg weekly for 4 weeks, then 0.5 mg, with gradual uptitration as tolerated 1. Rapid titration in volume-sensitive HF patients risks GI-driven dehydration and hemodynamic compromise.